Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer

BACKGROUND: Docetaxel–prednisone (DP) is an approved therapy for metastatic castration-resistant prostate cancer (mCRPC). Orteronel (TAK-700) is an investigational, selective, non-steroidal inhibitor of 17,20-lyase, a key enzyme in androgenic hormone production. This phase 1/2 study evaluated ortero...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Invest New Drugs
Päätekijät: Petrylak, Daniel P., Gandhi, Jitendra G., Clark, William R., Heath, Elisabeth, Lin, Jianqing, Oh, William K., Agus, David B., Carthon, Bradley, Moran, Susan, Kong, Ning, Suri, Ajit, Bargfrede, Michael, Liu, Glenn
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4390470/
https://ncbi.nlm.nih.gov/pubmed/25556680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0199-x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia